Metabolic interactions with statins;Metabolismeinteraksjoner med statiner

Tidsskrift for den Norske Laegeforening

Volumn 121, Issue 2, 2001, Pages 189-193

  Molden, E ^a   Asberg A ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CYTOCHROME P450 3A4; FLUINDOSTATIN; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

DRUG ELIMINATION; DRUG METABOLISM; DRUG POTENCY; ENDOPLASMIC RETICULUM; ENZYME ACTIVITY; REVIEW;

EID: 0035915734     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition
2. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions
3. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole
4. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin
5. Effect of itraconazole on the pharmacokinetics of atorvastatin
6. Effect of itraconazole on cerivastatin pharmacokinetics
7. Metabolism and drug interactions of 3-hydroxy-3methylglutaryl coenzyme A reductase inhibitors in transplant patients: Are the statins mechanistically similar?
8. New insights into the pharmacodynamic and pharmacokinetic properties of statins
9. Rational assessment of the inter-action profile of cerivastatin supports its low propensity for drug interactions
10. Disposition of pravastatin sodium, a tissueselective HMG-CoA reductase inhibitor, in healthy subjects
11. Biotransformation of pravastatin sodium in humans
12. Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver
13. The 3-hydroxy-3methylglutaryl coenzyme A reductase inhibitor fluvastatin: Effect on human cytochrome P-450 and implications for metabolic drug interactions
14. Cytochrome P4502C9: An enzyme of major importance in human drag metabolism
15. Effects of the antifungal agents on oxidative drug metabolism: Clinical relevance
16. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid
17. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations
18. Erythromycin coadministration increases plasma atorvastatin concentrations
19. Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin
20. Clinical pharmacokinetics of mibefradil
21. Rhabdomyolysis due to interaction of simvastatin with mibefradil
22. Drug inter-actions with calcium channel blockers: Possible involvement of metabolite-intermediate complexation with CYP3A
23. The interaction of diltiazem with simvastatin
24. The interaction of diltiazem with lovastatin and pravastatin
25. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study
26. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin
27. Grapefruit juice - Simvastatin interaction effect on serum concentrations of simvastatirt, simvastatin acid, and HMG-CoA reductase inhibitors
28. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid
29. Mechanism-based inactivation of human cytochrome P450 3A4 by grapefruit juice and red wine
30. Efficacy of statin therapy: Possible effect of phenytoin
31. St John's Wort: Effect on CYP3A4 activity
32. Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R- and S-warfarin enantiomers
33. Development and pharmacology of fluvastatin
34. Potential interaction between warfarin and fluvastatin
35. Lovastatin during warfarin therapy resulting in bleeding
36. The effect of converting from pravastatin to simvastatin on the pharmacodynamics of warfarin
37. Atorvastatin does not alter the anticoagulant activity of warfarin
38. Clinical pharmacokinetics of pravastatin
39. Preclinical and clinical pharmacology of cerivastatin
40. Rhabdomyolysis and acute renal failure due to combination therapy with simvastatin and warfarin
41. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients
42. Efficacy and pharmacokinetics of simvastatin in heart transplant recipients
43. Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients
44. Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine
45. A prospective study on treatment of hypercholesterolemia with lovastatin in renal transplant patients receiving cyclosporine
46. Cerivastatin and atorvastatin: Efficacy, safety and drug inter-action of the new HMG-CoA reduktase inhibitors in renal transplant patients
47. The interaction of fluvastatin and cyclosporin A in renal transplant patients
48. Accumulation of lovastatin, but not pravastatin, in the blood of cyctosporine-treated kidney graft patients after multiple doses